noom oral semaglutide Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree Noom expands its GLP-1 range

Description

News provided by Havas Worldwide, LLC Jun 17, 2024, 03:00 ET The network will deliver tailored resources for brands to adapt to the dynamic landscape and adjacent markets accelerated by disruptor drugs, like GLP-1s NEW YORK, June 17, 2024 /PRNewswire/ - Today, Havas announced the launch of its internal consultancy service designed to drive meaningful strategic solutions in response to disruptive innovations, such as GLP-1s

Discard the WEGOVY pen after use

Pendulum has a 2-3 minute online health survey to verify HSA/FSA eligibility

We had assumed it was a consequence of losing weight but this seems to suggest theres a separate pathway. We dont know how those effects would play out in patients at a healthy weight, because they werent part of the study so it doesnt mean that semaglutides should be considered as a treatment for anyone with heart issues regardless of their weight